Experimental drug shows promise for Hard-to-Treat lymphomas
NCT ID NCT00875056
First seen Feb 01, 2026 · Last updated May 04, 2026 · Updated 15 times
Summary
This study tested a drug called vorinostat in 56 people with follicular lymphoma or other slow-growing B-cell lymphomas that had returned or stopped responding to prior treatments. The main goal was to see if the drug could shrink tumors and to check its safety. The study was completed and measured how many patients had a complete or partial response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.